Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Spine|January 1, 1988
The lumbar facet syndromeT Helbig, C K Lee
Immunotherapy|April 6, 2013
Adjuvant immunotherapies as a novel approach to bacterial infectionsElisa T Helbig, Bastian Opitz, Leif E Sander
AMIA ... Annual Symposium Proceedings. AMIA Symposium|January 20, 2004
Are electronic medical records trustworthy? Observations on copying, pasting and duplicationKenric W Hammond, Susan T Helbig, Craig C Benson, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 17, 2021
Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational studyBarbara Mühlemann, Charlotte Thibeault, David Hillus, et al.
Journal of Global Antimicrobial Resistance|December 26, 2022
Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trialFlorian Kurth, Elisa T Helbig, Lena J Lippert, et al.
Infection|April 14, 2022
Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort studyTilman Lingscheid, Lena J Lippert, David Hillus, et al.
JCI Insight|March 7, 2023
Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19Charlotte Thibeault, Lara Bardtke, Kanika Vanshylla, et al.
Emerging Infectious Diseases|June 8, 2021
Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021Pinkus Tober-Lau, Tatjana Schwarz, David Hillus, et al.
The Lancet. Respiratory Medicine|August 15, 2021
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort studyDavid Hillus, Tatjana Schwarz, Pinkus Tober-Lau, et al.
Nature Immunology|March 21, 2018
Recognition of microbial viability via TLR8 drives T<sub>FH</sub> cell differentiation and vaccine responsesMatteo Ugolini, Jenny Gerhard, Sanne Burkert, et al.
Pageof 2